Organisation paid for research Program year 2023 Source: CMS Open Payments

WRClinSearch

Neither a doctor nor a teaching hospital

Research payments

$487,151

34 payments

Through program year 2023, WRClinSearch is reported as receiving $487,151 in research payments, across 34 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$404	1
2021	Research	$800	2
2019	Research	$485,947	31

Breakdown

Who paid Research payments · program years 2019–2023

Allergan Inc. $486,747 33 payments
Pfizer Inc. $404 1 payment

Studies the money was for Research payments · program years 2019–2023

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $355,661 16 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $76,108 6 payments
12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $24,167 1 payment
Open-Label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis Nash $12,961 4 payments
A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $11,378 2 payments
A 46-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Longterm Study With A 6-Week Randomized-Withdrawal Period to Evaluate the Safety and $5,672 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $600 1 payment
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $404 1 payment
A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine $200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.